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ABSTRACT

In previous studies from this lab, an alpha7 nACh receptor was found to successfully
modulate retinal ganglion cell neuroprotection against glutamate assault when bound to nicotinic
acetylcholine receptors, or if an alpha7 nicotinic acetylcholine agonist, such as PNU-282987 was
used in in vitro models (Wehrwein et al., 2004; Iwamoto et al., 2013). These in vitro studies
support the hypothesis that activation of alpha7 nicotinic ACh receptors triggers neuroprotection
against loss of retinal ganglion cells normally induced by excessive glutamate insult. The results
from these in vitro studies instigated an in vivo study in our lab using a rat glaucoma model.
However, further testing and manipulation of the specific alpha7 nAChR is required to
confidently provide evidence concerning ACh receptor’s modulatory capabilities. Therefore in
our lab, a variety of acetylcholine agonists that bind to ACh receptors, like PNU-282987 and
PHA 568487, will be used to analyze alpha7 nAChR neuroprotection in a rat model of glaucoma.
In addition, an acetylcholinesterase inhibitor, Donepezil, will be administered to determine if
inhibition of the acetylcholinesterase that normally degrades ACh, elicits a neuroprotective
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response normally associated with activation of ACh receptors. Adult Long Evans rats will be
used in in vivo glaucoma models, and the survival of retinal ganglion cells will be visualized
using a Zeiss confocal microscope with Metamorph software. ANOVA statistical analysis will
be performed on retinal ganglion cell survival in glaucoma-induced retinas and compared to
control untreated retinas to provide evidence that activation of alpha7 nAChRs prevents loss of
retinal ganglion cells in glaucoma. The long-term aim of this study is to find therapeutic
preventative treatments against glaucoma and other neurodegenerative diseases.

INTRODUCTION
Anatomoy of the Eye
To understand the mechanisms behind glaucoma and the proposed therapeutic treatments
in this thesis, it is necessary to have an understanding of the basic anatomy of the human eye
(Figure 1). The human eye is composed of two separate chambers: the anterior chamber which is
composed of a fluid called aqueous humour and the posterior chamber which is composed of a
fluid called vitreous humour. In addition, the eye is segregated into three separate layers of
tissue: the superficial layer is called the sclera, the middle layer is called the uvea, and the
innermost layer is called the retina (Schwartz, 1999). The sclera is composed of a layer of tough,
white fibrous tissue that works to provide protection and support for the eye. The anterior aspect
of the sclera forms a transparent tissue called the cornea which is composed of transparent
collagen fibers arranged in a lattice network that works to enable environmental light rays to
enter the eye (Lens et al., 1999).
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Figure 1
Anatomy of the human eye. (Image taken from the Glaucoma Research Foundation Website at
http://www.glaucoma.org/glaucoma/anatomy)

The middle layer of tissue, the uvea, involves three distinct structures: the iris, the ciliary
body, and the choroid. The iris is the colored part of the anterior portion of the eye. It is made up
of two sets of smooth muscles under neural control that function to adjust the size of the opening
at the center of the iris called the pupil. The ciliary body encircles the lens and is composed of
both muscular and vascular structures. The muscular component of the ciliary body allows for
the adjustment of the refracting power of the lens while the vascular component, also referred to
as the ciliary processes, produces the fluid or aqueous humour that fills the anterior chamber and
serves to nourish both the cornea and the lens. Lastly, the choroid is composed of a large
capillary bed that functions as the main blood supple for the photoreceptors of the retina, the
innermost layer of the eye (Purves et al., 2001).
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The retina is the innermost tissue layer found within the posterior aspect of the eye. The
retina is part of the central nervous system and it consists of a multitude of cells that function to
translate visual information in the form of light stimuli into electrical signals that are then
transported to the brain for interpretation purposes. This process is called phototransduction and
the cells within the retina involved in this process include: photoreceptors (rods and cones),
horizontal cells, bipolar cells, amacrine cells, and retinal ganglion cells (RGCs) (Figure 2). The
primary focus of this thesis is concerned with RGCs and their role in visual perception.

Figure 2.
Anatomy of the retina. A visual signal is converted into an electrical impulse at this layer of
tissue. The cells involved in this conversion include: photoreceptors (rods and cones), bipolar
cells, horizontal cells, amacrine cells, and retinal ganglion cells. (Image adapated from
WebVision at http://webvision.med.utah.edu/imageswv/schem).

Light that enters the eye is directed to a location of the retina called the fovea centralis. It
is at this particular spot that the maximal visual acuity can be realized. This is true because it is at
this specific location that the greatest number of rods and cones, photoreceptors involved in the
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conversion of light into electrical signals, are found. Rods are responsible for dark and dim
vision, whereas, cones are responsible for color vision. Typically, rods are found throughout the
retina and in the periphery while cones are concentrated more specifically at the fovea.
Once light enters the eye and stimulates the photoreceptors, the visual signal is then
transferred to the retinal ganglion cell layer with the aid of the bipolar cells, horizontal cells, and
starburst amacrine cells. The bipolar cells are interneurons that are connected vertically to both
the photoreceptors and RGCs. The horizontal cells synapse on the photoreceptors and are
responsible for regulation of the visual signal. The starburst amacrine cells are found displaced
among RGCs and, along with the bipolar cells and horizontal cells, play a role in transmission of
the visual signal. The axons of the RGCs form the optic nerve which transfers the electrical
signal to the brain where visual processing occurs.
Starburst amacrine cells are of interest in this thesis not only because of their role in the
regulation of the visual signal, but also because they serve as the only source of acetylcholine
within the retina. This is significant because given that studies have shown acetylcholine to be an
important endogenous neurotransmitter linked to the protection of cells within the central
nervous system (Thompson et al., 2006). It is this protective mechanism that may in fact suggest
another role of starburst amacrine cells, a role devoted to preventing neuron cell death.

Phototransduction
Phototransduction begins when a photon of light isomerizes rhodopsin, an integral
membrane protein found within photoreceptors. This isomerization elicits a conformational
change in rhodopsin, converting the 11-cis retinal structure to an 11-trans retinal structure. Once
activated, rhodopsin stimulates transducin, a GTP binding protein,that subsequently activates
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cGMP phosphodiesterase, an enzyme found in the cytoplasm of photoreceptor cell. The
activation of cGMP phosphodiesterase results in a decrease in cytoplasmic cGMP which closes
cGMP-gated cation channels and hyperpolarizes the photoreceptor membrane, which serves as
the beginning of sight, by decreasing the amount of the photoreceptor neurotransmitter,
glutamate, from being released (Houbin, 2003).
Photoreceptors are connected vertically to bipolar cells which synapse onto RGCs. There
are two types of bipolar cells, OFF cells and ON cells. The difference between the two lies in the
type of glutamate receptor expressed on their membrane. The OFF bipolar cells contain an
ionotropic glutamate receptor, whereas, the ON bipolar cells express a metabotropic glutamate
receptor. In a dark state, glutamate is continuously released and synapses with OFF bipolar cells,
thus, depolarizing the bipolar cell membrane. However in a light state, when a photon elicits a
response that acts to decrease glutamate release, the OFF bipolar cells become hyperpolarized.
However, the ON bipolar cells’ response to such a decrease in synaptic glutamate concentration
is depolarization which serves to generate an electrical signal that can then propagate to RGCs
(Massey and MIller, 1987).
The electrical signal is transferred to RGCs by synaptic glutamate release which elicits
RGC depolarization when glutamate is bound to an excitatory kainate receptor on RGCs
membrane. The axons of RGCs then converges at the optic nerve head, found at the posterior
aspect of the eye, and axons travel to the lateral geniculate nucleus of the thalamus. From this
location on the thalamus, the signal is then propagated to the visual cortex, the site of visual
perception within the occipital lobe of the brain (Gao et al., 2013).

Glaucoma
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Glaucoma is a retinal degenerative disease that results in optic neuropathy, cupping of the
optic disk and retinal ganglion cell death, leading to visual field loss and blindness (Guo et al.,
2005). High risk groups include African Americans, those over the age of 60, those whose family
members were previously diagnosed, and diabetics. Glaucoma is characterized most frequently
by a subsequent increase in intraocular pressure (Morrison et al., 1997; Chauhan et al., 2002;
Levkovitch-Verbin et al., 2002). This increase in intraocular pressure is believed to be caused by
a blockage or back-up within the eyes’ filtration system, the trabecular meshwork. Such a block
prevents the outflow of aqueous humor, fluid within the anterior chamber of the eye that
provides nutrients and oxygen to the eye. Blockage of aqueous humor results in a build-up of
pressure within the anterior part of the eye, leading to an overall increase in intraocular pressure.
This build up of pressure, pushes on the suspensory ligaments of the lens and applies pressure to
the retina, resulting in loss of retinal ganglion cells. However treatment to hinder the effects of
glaucoma focus only on reducing intraocular pressure, and in some cases, this treatment proves
to be insufficient to prevent the onset and progression of glaucoma, suggesting that other
treatments could be developed to prevent the loss of retinal ganglion cells.

Excitotoxicity
Excitotoxicity, or neuronal cell death caused by excessive excitatory neurotransmitters,
has been shown to have some correlation with visual field loss characteristic of retinal
degenerative diseases such as glaucoma, as well as, retinal ischemia, and diabetic retinopathy
(Quigley, 1998, Choi., 1988, Lafuente et al., 2001). In particular, glutamate induced
excitotoxicity may be the missing component to understanding glaucoma and retinal ganglion
cell death that is not associated with increased intraocular pressure. Glutamate is an excitatory
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neurotransmitter released by bipolar cells and photoreceptors within the retina (Ehinger et al,
1988; Marc et al., 1990; Jujich and Pourcho, 1996). In previous research, an excessive amount of
glutamate in the vitreous humor within the posterior chamber of the eye showed to propagate an
influx of calcium into the retinal ganglion cells through glutamate receptor channels, initiating an
apoptotic signaling cascade and leading to retinal ganglion cell death (Olney, 1977; Choi, 1987;
Manev et al., 1989). Death of RGCs prevents the visual signal from being conveyed to the brain,
thus resulting in visual field loss.

Neuroprotection
One proposed mechanism to protect against excitotoxcity is through neuroprotection of
retinal ganglion cells. Neuroprotection is defined as the process of hindering excitotoxic events
by inducing a protective mechanism to cease apoptotic cascades. Previous studies have
demonstrated that acetylcholine and nicotine can provide neuroprotection against glutamate
induced excitotoxicity (Wehrwein et al. 2004). Another study then determined that the specific
nicotine acetylcholine receptor, an alpha7 nAChR, mediates neuroprotection (Brandt et al. 2011).
However to deduce whether activation of this specific alpha7 nAChR provided neuroprotection
of RGCs lost in association with glaucoma, a study was done that used an alpha7 nicotine
agonist, PNU 282987, in an in vivo rat model experiments. An agonist works by mimicking the
effects of nicotine and/or acetylcholine on the nAChR. This study demonstrated that the
neuroprotective effects of PNU 282987 under glaucoma-like conditions prevented RGC loss
within the retina, signifying that RGC loss is mediated through an alpha7 nAChR (Iwamoto et al.
2013).
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The main objective of this Honors thesis project is to more thoroughly test and provide
clearer evidence that the alpha7 nAChR is responsible for RGC neuroprotection by testing
multiple alpha7 nAChR agonists such as, PNU-282987 and PHA-568487, and the
acetylcholinesterase inhibitor, Donepezil. Acetylcholinesterase is an enzyme that acts to degrade
acetylcholine from its receptor, thus ceasing acetylcholine’s neuroprotective effects on retinal
ganglion cells. However, if a specific acetylcholinesterase inhibitor was used to stop this
enzyme’s activity, by preventing acetylcholinesterase from degrading acetylcholine from the
alpha7 nAChR, the hypothesis is that it will result in prolonged protection of the RGCs and
prevent retinal degeneration and death.

PNU-282987
PNU-282987 (N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride) is
an alpha7 nAChR agonist that was originally designed by Pharmcia and Upjohn for the treatment
of schizophrenia with the intent of providing neuroprotection to the neurons in the brain (Bodnar
et al, 2005). However, its systemic use was found to cause detrimental effects in the heart by
fostering inhibition of essential potassium channels (Walker et al., 2006). Although, systemic
application was found to be unviable in treatment against schizophrenia, in glaucoma the use of
PNU-282987 in localized application by way of eye drops had proved to be both attainable and
effective without the aforementioned detrimental systemic effects.
In previous studies from our lab, bi-daily drops of 1 mM PNU-282987 applied for three
days prior to inducing a glaucoma-like environment followed by one month post procedure
application, have demonstrated pronounced RGC neuroprotection effects. In addition,when
applied as eye drops, no trace of PNU-282987 was found in cardiac tissue, thus, proving
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evidence that the previously hindering effects of systemic application is not applicable for
consideration when using local eye drops (Mata, 2013).
PHA-56487
PHA-56487 (N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5carboxamide) is a specific alpha7 nAChR agonist developed for the therapeutic treatment against
cognitive deficits in people with schizophrenia and Alzheimer’s disease. PHA-56487 has been
shown to be active in both in vitro and in vivo studies (Acker et al., 2008). It is capable of rapidly
penetrating the blood brain barrier and accomplishing effective auditory sensory gating and
object recognition in an in vivo rat model (Wishka et al., 2006). Due to their specificity to alpha7
nAChRs, both PNU-282987 and PHA-56487 were used in this neuroprotective study.
Donepezil
Donepezil is a selective and reversible acetylcholinesterase inhibitor that is produced by
both Pfizer and Eisai under the trade name Aricept. It is used for the therapeutic treatment of
mild to moderate Alzheimer’s disease. It binds to peripheral anionic sites and delays amyloid
plaque deposition by maintaining acetylcholine levels in the brain (Colovic et al., 2013). As the
use of Donepezil may enhance the neuroprotective effect of ACh released from the starburst
amacrine cells onto RGCs, donepezil was used in this study as well.

Although these drug treatments seem promising, other cellular factors may come into
play preventing the desired prolonged neuroprotection. Therefore, the goal of this thesis was to
manipulate the amacrine cell to RGC synapse and analyze whether application of drugs such as
Donepezil, PNU-282987, and PHA-568487 alone or in combination would result in preventing
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retinal ganglion cell death and subsequent blindness in our glaucoma model. Results from these
studies could lead to an alternate protective therapeutic treatment to prevent glaucoma.

Method
Animals
Male and female adult Long Evans rats between the ages of 3 to 6 months were used for
this study. Animals were purchased from the Charles Rivers Lab in Portage, MI, and held at
Western Michigan University’s animal facility for research purposes. All animals were handled
and cared for under the guidelines set forth by the Institutional Animal Care and Use Committee
of Western Michigan University in accordance with IACUC protocol.

Inducing a Glaucoma-like Environment
The procedure to induce glaucoma in Long Evans rats used in this experiment has
previously been published by Iwamoto et al. (2014). Rats were anesthetized via a 1ml/Kg
interperitoneal injection of KAX, a cocktail consisting of 5 mL of ketamine (100mg/mL), 2.5 mL
of xylazine (20mg/mL), 1 mL of acepromazine (10mg/mL), and 3 mL of sterilized water. The
procedure was initiated once there was no indication of reflex activity. This was tested by pulling
on the hind legs and/or pinching the skin.
To establish a glaucoma-like conditions, 50 µl of 2M NaCl was injected into the
episcleral veins of each anesthetized experimental rat’s right eye. This creates scar tissue in the
trabecular meshwork that decreases the outflow of aqueous humor from the anterior chamber of
the eye (Morrison et al., 1997). The effect is a slow build-up of intraocular pressure that mimics
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the main risk factor associated with glaucoma. A glass needle, 40 micrometer in diameter, was
pulled from a Narishige electrode puller to be used for the injection. The glass needle was
attached to tapered polyethylene tubing (PE-50, Clay Adams, Parsippan, NJ) that was then
placed into a 23-gauge needle with the tip filed off. The glass needle’s tip was then beveled to
allow for easy penetration into the episcleral vein upon injection of saline into the right eye of
the animals (the left eye was left untreated and used as an internal control). The saline causes
blanching within the episcleral vein and was used as an indicator of successful injection.
Following the procedure to induce glaucoma, antibiotic cream was applied to the rat’s right eye
and the rat was returned to its cage where it was monitored until it was fully awake, prior to
being placed back within the animal facility.

Drug Application
To determine the effects of PNU-282987, PHA-568487, and Donepezil, one drop of each
drug was applied to the right eye of the specified rats (three rats for PNU-282987, 3 rats for
PHA-568487, 3 rats for donepezil, and 3 rats for PNU-282987 and Donepezil in combination),
twice a day for three days prior to surgery to induce glaucoma. This initiated the preventative
neuroprotective mechanism of RGCs in the retinal ganglion layer. Following the procedure to
induce glaucoma, PNU-282987 alone was applied as eye drops twice daily to the right eye of 3
rats for three weeks. Bi-daily drop application was deemed necessary based on previous studies
that found detectable levels of PNU-282987 in the retina for up to twelve hours after eye drop
application (Mata, 2013). The same procedure was conducted with Donepezil, PHA-568487, and
Donepezil and PNU-282987 respectively.

One exception was animals treated only with

donepezil were only treated once each day. This was deemed sufficient based on previous studies
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showing detectable levels twenty-four hours following application (Acker et al., 2008, Colovic et
al., 2013, and Wishka et al., 2006).
All eye drop solutions were made up as 100 mM using DMSO and then diluted down to 1
mM using PBS for PNU and PHA compounds to 100 µM for Donepezil. Preliminary dose
response studies demonstrated that these concentrations of each agent provided the maximal
neuroprotective response.

Retina Isolation and RGC Quantification
One month following the procedure to induce glaucoma, animals were euthanized by
carbon dioxide asphyxiation and both control and experimental eyes from each rat were
surgically removed. A coronal slit was then made in the animals’ eyes and surgical scissors were
used to cut around the circumference of the eye in such a way that upon completion, anterior and
posterior eyecups are made. The anterior eyecup, the lens, and the vitreous humour were
discarded and the retina was carefully removed, in one piece, from the posterior eyecup after
detaching the optic nerve. Four slits, 90 degrees apart, were then made at the periphery of all four
quadrants of the retina in order to flat mount the retinas onto sylgard plates. Cactus needles were
used to pin the retinas to the plates. The retinas were then fixed with 10% formalin overnight at 4
degrees C. Following fixation, the retinas were then rinsed with PBS and incubated with a
specific antibody agonist Thy 1.1 in PBS (1:300 dilution) containing .02% saponin for one week
at 4 degrees Celsius in a dehumidified chamber. Thy 1.1 is a mouse anti-rat IgG glycoprotein
found exclusively on retinal ganglion cells in the retina (Barnstable and Drager, 1984).
Following the conclusion of one week, the retinas were then washed three time with PBS
and incubated in a secondary goat antibody, Alexa Fluor 595 (1:300 dilution), for 5 days at 4
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degrees C. for microscopic viewing purposes. Alexa Fluor 595 is a goat anti-mouse IgG
(Invitrogen Molecular Probes). After 5 days, the retinas were then rinsed three times with PBS
and transferred to glass slides with coverslips and mounted using a 50% glycerol and 50% PBS
solution.
After fluorescently labeling RGCs, they were viewed using the 60 x objective lens of a
Zeiss confocal microscope from each quadrant of the retina. Images were obtained in 1 micron
increments transversely through the retinal ganglion cell layer at a location of 400 micrometers
from the ONH, (optic nerve head) (Figure 3). Four images were taken from each quadrant of
each retina and averaged to obtain the most accurate RGC survival data using Metamorph
software. Thy1.1 labeled RGCs were counted using an 100 micrometer frame in Metamorph
software. The total frame area was divided by the total cell area (axons were not included in this
number) to obtain a percentage that was then applied to the visible cell count to determine the
theoretical cell count. This method was used to ensure that the cells covered by axons and
subsequently not visualized were accounted for.

Figure 3 Image of a Flat Mount Retina.
The yellow boxes represent the areas 4 mm from the optic nerve head where RGC images were
obtained.
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Statistical Analysis
To analyze the effects of the drug treatments, RGC counts in experimental eye retinas
were compared to their respective internal control retina using Student T-tests. All values were
documented with the mean standard error of the sample-mean. A value of p < 0.05 was
considered statistically significant.

Results
Effects of Glaucoma Induction on RGC
In order to determine the effects on RGCs in a glaucoma like environment, the episcleral
vein of the right eyes of the tested rats were injected with 50 µl of 2mM NaCl. This fostered scar
tissue formation in the trabecular meshwork, which served to increase intraocular pressure, a
main risk factor associated with glaucoma. One month following saline injection, the retinas
were removed and processed with antibodies against Thy1.1 glycoprotein, a protein found on the
RGC plasma membrane. The RGCs were then counted and compared to their respective left
internal controls. It was found that glaucoma induction surgery alone caused a 26% (± 1.5, N=3)
decrease in RGCs (figure 5). This is a statistically significant difference from the control eye.
Effects of PNU-282987 on RGC
In order to determine the effects of PNU-282987 on RGC in an induced glaucoma state,
1mM of PNU-282987 was applied to right experimental rat eyes in a bi-daily drop-wise manner
for three days preceding glaucoma induction surgery and for three weeks following surgery. One
month after surgery, the retinas were removed and processed with antibodies against Thy1.1
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glycoprotein, a protein located on the RGC plasma membrane. The RGCs were then counted and
compared to their respective left internal control. It was found that after 1 mM of PNU-282987
drop-wise treatment, there was only a 7% (± 2.8, N=3) decrease in RGC total (Figure 4). This is
a statistically significant difference from the control eye. The collected results show a
pronounced improvement from the 26% decrease in RGC counts that normally follows glaucoma
induction surgery (Figure 5) (Mata 2013).

Figure 4. Right and Left Eye Images from a Glaucoma Induced Rat treated with PNU282987
The right image is the experimental retina, the eye that had undergone glaucoma induction and
PNU-282987 treatment. The left image is the left eye and the internal control. This eye did not
undergo glaucoma induction or PNU-282987 treatment.

Figure 5. Right and Left Eye Images from a Glaucoma Induced Rat with No Treatment
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The right image is the experimental retina, the eye that underwent glaucoma induced surgery
without receiving treatment. The left image is the internal control retina, the eye that did not go
through glaucoma surgery and did not receive any treatment.
Effects of PHA-568487 on RGC
In order to determine the effects of PHA-568487 on RGC in an induced glaucoma state, 1
mM of PHA-568487 was applied to the right experimental eyes of rats in a daily drop-wise
manner for three days prior to surgery to induce glaucoma and for three weeks following
surgery. One month after surgery, eyes were removed and retinas were processed with antibodies
against a Thy1.1 glycoprotein on the RGC membrane. RGCs were counted and compared to
internal controls. It was found that 1 mM of PHA-568487 had provided a 43% (± 21, N=3)
increase in RGC. This is a statistically significant difference from the untreated control counts.
The collected data shows that PHA-568487 alone would be sufficient in preventing RGC loss in
a glaucoma-like environment. However, this data also suggests that PHA-568487 may be
capable of fostering a proliferation-like effect on RGC given the substantial increase in cell
counts.

Figure 6. Right and Left Eye Images from a Glaucoma Induced Rat treated with PHA568487
The right image is the experimental retina, the eye that underwent surgery to induce glaucoma
and PHA-568487 treatment. The left image is the internal control retina, the eye that did not
undergo glaucoma induction surgery and did not receive PHA-568487 treatment.
Effects of Donepezil on RGC
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In order to determine the effects of Donepezil on RGC in a glaucoma-like environment,
100 micromoles of Donepezil was applied to the right experimental eyes of rats in a daily dropwise manner for three days proceeding glaucoma inducing surgery and for three weeks following
surgery. One month after surgery, eyes were removed and retinas were processed with antibodies
against Thy1.1 glycoprotein found on the membrane of RGC. RGCs were counted and compared
to internal controls. It was found that 100 micromoles of Donepezil produced a 36% (± 11, N=3)
increase in RGC numbers (Figure 7). This is a statistically significant difference from untreated
control counts. The collected data is evidence that Donepezil alone is sufficiently capable of
protecting against RGC degradation in a glaucoma-like environment. However in addition to this
protection, the data also suggests that Donepezil may in fact foster an additional proliferationlike effect within the retina.

Figure 7. Right and Left Eye Images from a Glaucoma Induced Rat treated with Donepezil
The right image is the experimental retina, the eye that underwent glaucoma induction surgery
and Donepezil treatment. The left image is the internal control retina that did not undergo
surgery or treatment.
Effects of Donepezil and PNU-282987 on RGC
In order to assess the combined neuroprotection of an acetylcholinesterase inhibitor and
an alpha7 nAChR agonist on RGC in a glaucoma induced environment, a cocktail of 100
micromoles of Donepezil and 1 mM of PNU-282987 was applied in a daily drop-wise manner to
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the right experimental eyes of rats for three days prior to glaucoma induction surgery and for
three weeks following surgery. One month after surgery to induce glaucoma, eyes were removed
and retinas were processed with antibodies against Thy1.1 glycoprotein on the RGC membrane.
RGCs were counted and compared to internal controls. The combined effects of Donepezil and
PNU-282987 provided a 3.7% (± 6.5, N=3) increase in RGC counts (Figure 8). This is a
statistically significant difference when compared to internal control counts. This data suggests
that the combination of an alpha7 nAChR agonist and acetylcholinesterase inhibitor was
effective at preventing RGC degradation in a glaucoma-like environment. The slight increase in
RGC was not significantly different from control untreated counts.

Figure 7. Right and Left Eye Images from a Glaucoma Induced Rat treated with Donepezil
and PNU-282987.
The right image is the experimental retina, the eye that underwent glaucoma induction surgery
and treatment with Donepezil and PNU-282987. The left image is the internal control retina, this
eye did not undergo glaucoma induction surgery or treatment.
The aforementioned results of the pharmacological drop treatments used in this study are
easily visualized and conveniently summarized in Figure 8, which shows the respective increase
and decrease in RGC numbers when compared to internal controls (x axis).
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Figure 8. Percentage of RGC Damage After Procedure to Induce Glaucoma.
Rats that underwent the procedure to induce glaucoma had a 26% decrease of RGC. Rats that
underwent the glaucoma-induction procedure and treatment of 1 mM PNU-282987 had only a
7% decrease of RGC. However, rats that underwent the glaucoma-induction procedure and
treatment of 1 mM of PNU-282987 with 100 micromoles of Donepezil, 100 micromoles of
Donepezil alone, and 1 mM of PHA-568487 all showed an increase in RGC of 3.7%, 36%, and
43% respectively. This increase appears to be suggestive of a proliferation-like effect on RGC
subjected to the aforementioned treatment in that more cells are accounted for than what was
visualized in their respective internal controls.
Discussion
All of the tested pharmacological drops provided some sort of protection against RGC
loss that is typically of the glaucoma inducing treatment. However, some of the treatments went
beyond protection and showed evidence of proliferation. Being that the cells under analysis are
adult mammalian neurons which typically do not go through mitotic division, this concept of
proliferation of retinal ganglion cells was unexpected. However after further research, it was
discovered that the noted proliferation-like effect upon activation of an alpha7 nAChR is not an
entirely novel finding. In fact, previous studies have reported similar observations with an alpha7
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nAChR found associated with neurons in the granular cell layer of the hippocampus and
olfactory bulb.
In one study, both Donepezil and PHA-568487 were used to analyze neuron proliferation.
In this study, it was found that PHA-568487 was successful at promoting proliferation in the
granular cell layer of the dentate gyrus (an area of the hippocampus). However, no such
proliferation or survival effect was noted with the administration of Donepezil (Kita et al., 2014).
Whereas the former finding on the proliferation potential of PHA-568487 is consistent with the
findings in this thesis, the latter data is inconsistent with both this study’s findings and a previous
study’s findings that analyzed both acute and chronic Donepezil treatment in a stress-induced rat
brain model.
In the stress-induced rat brain model, rats were placed in close-fit cylinder restrainer for 6
hours every day for 4 weeks to mimic a stressful environment, Donepezil (both acute or shortlived treatment and chronic or long-term treatment) was administered, and neurons in the
dendate gyrus and olfactory bulb areas of the brain were counted. It was found that chronic
Donepezil treatment promotes the survival of newborn neurons in a stress-induced state but does
not effect the proliferation of progenitor cells (pluripotent stem cells). On the other hand, acute
Donepezil treatment showed to increase cell proliferation but had no long term effects on
newborn neurons’ survival (Kaneko et al., 2006).
It was hypothesized that these contrasting results may be in relation to treatment duration.
Immediately following Donepezil treatment, the extracellular ACh concentration is greatly
increased, thus fostering acute proliferation-like effects. However over time with chronic
Donepezil treatment, these effects may become less significant and equilibrated by the downregulation of other AChRs found on the neuron membrane (Kaneko et al., 2006). Although this
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thesis’s focus did not analyze varying treatment durations with Donepezil or other
pharmaceutical drops, the results of the Donepezil study on neuron survival and proliferation
potential are consistent with this thesis’s results, which essentially shows that Donepezil and
other drop treatments can protect against neuron loss in a stress-and/or glaucoma-induced state.

The mechanism behind the initiation of an additional mitotic division or proliferation is
not currently known. However, three out of four of the specific drop treatments tested in this
thesis had suggested some sort of proliferation-like effects. These findings were noted in
treatment regimens that include: PHA-568487, Donepezil, and PHA-282987 in combination with
Donepezil. In fact, the only treatment used that did not show evidence of proliferation was found
in the rats who received 1 mM of PNU-282987 drop-wise solution.
When comparing the experimental retinas of Figure 4 and 5, it is evident that the RGC
density is greater in the retinas that had received the PNU-282987 treatment (Figure 4) then in
the retinas that had not. In addition, the RGCs of the eye that had not received treatment (Figure
5) appear less round and uneven in comparison to the treated eye (Figure 4). These observations
suggest that PNU-282987 provides some level of neuroprotection against glaucoma. This
scenario was validated based on the data that shows that PNU-282987 prevented the average loss
of 17% of RGCs normally lost during the glaucoma inducing procedure. However, complete
protection was not provided by PNU-282987 alone, thus suggesting that 1 mM of PNU-282987
is incapable of eliminating RGC loss in a glaucoma state. These findings are consistent with a
previous study in the lab that showed that 1mM of PNU-282987 caused 6.9% RGC loss when
compared to internal controls. However, this previous study also analyzed the effects on RGCs
following 10 mM of PNU-282987 and it was found that with 10 mM of PNU-2282987, there
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was a 13.5% increase in RGC density, thus suggesting that PNU-282987 is capable of fostering
proliferation if a higher concentration is utilized (Mata 2013).
Contrary to these PNU-282987 results, PHA-568487, another alpha7 nAChR agonist,
was analyzed for neuroprotective effects and showed an increase of 43% in RGC count. When
compared to PNU-282987, which showed a moderate decrease in cell loss but no increase in cell
numbers, PHA-568487 may prove to be an even better and more specific target for
neuroprotection of retinal ganglion cells. These findings are consistent with the aforementioned
study on brain tissue, which showed proliferation-like effects in cells treated with PHA-568487
(Kita et al., 2014).
In addition to assessing the effects of two different alpha7 nAChR agonists, Donepezil a
acetylcholinesterase inhibitor, was also tested. Donepezil functions to prolong agonist binding to
the alpha7 nAChR and it was suspected that by using Donepezil in conjunction with an alpha7
nAChR agonist, an even greater neuroprotective and possible proliferation effect might ensue.
However before this study was done, it was necessary to assess the effects of Donepezil alone in
order to establish a baseline marker that would allow for better stratification of its effects when
used with an alpha7 nAChR agonist.
Donepezil by itself, had a larger effect of RGC survival than PNU-282987. After PNU282987 treatment, there was an average RGC loss of 7% compared to Donepezil’s 36% increase
in RGCs. The combination treatment of Donepezil and PNU-282987 was not as effective as
Donepezil alone, as the combined treatment only resulted in a 3.7% increase in RGCs. The
subsequent next step would be to assess the combined effects of Donepezil and PHA-568487 and
analyze varying concentrations of PNU-282987, alone and with Donepezil, in order to,
determine if a better neuroprotective and proliferation-like effect is found. However due to both
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time constraints and resources, the combination of PHA-568487 and Donepezil was not
evaluated in this study.

Future Application
As previously mentioned, the next step would be to complete this study by analyzing the
combined effects of Donepezil and varying concentrations of both PNU-282987 and PHA568487 to develop a better idea as to what concentrations provide the most positive proliferative
and neuroprotective effect on retinal ganglion cells. From there, a closer analysis of the specific
mechanisms behind both the survival and proliferation effects is necessary to develop the best
treatment against neurodegenerative diseases, such as, glaucoma.
In addition, further investigation into the identity and capabilities of what appears to be
proliferated cells is warranted. If these cells are in fact retinal ganglion cells, then one is left to
question as to whether these cells function in accordance with RGC. Are these additional cells
capable of relaying the electrical impulse initiated by a visual stimuli to the brain as part of
visual processing? At some point, a visual test would be necessary to determine whether the
retinal ganglion cells protected by the pharmacological drops in this study are actually
improving, or at the very least, sustaining one’s visual potential.
Lastly, seeing that glaucoma is one type of neurodegenerative disease, future aims should
be directed toward identifying the similarities and differences between the retina and the brain in
hopes of discovering better treatment and/or a cure for neurodegeneration. Other
neurodegenerative diseases that would be targeted include: Alzheimer’s and Parkinson’s.
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The results of this study show that PNU-282987, PHA-568487, and Donepezil, separately
and in combination, are capable of providing neuroprotection against the onset of glaucoma.
However as previously mentioned, further dosage and behavioral studies are warranted (Mata
2013; Iwamoto et al., 2014). Nonetheless, the pharmacological drops in this study have the
potential to serves as a novel drop-wise treatment option to prevent against, and possibly, with
further research, one day reverse, the onset of glaucoma, thus, improving the vision and overall
livelihood of the sector of our population that this life-altering disease affects.
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